Skip to content

Care augmentation by location-linked messaging

Assessment of Care Augmentation by Location-Linked MEssaging in amyotrophic lateral sclerosis with respiratory impairment compared with current standard care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN71271888
Enrollment
20
Registered
2015-01-12
Start date
2017-06-01
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis Nervous System Diseases

Interventions

A smartphone running the Android operating system will be loaded with a custom designed app specifically designed to send text messages to predefined members of the patient's care team when the phone

Sponsors

King's College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of ALS 2. Subjects of either sex aged 18 years or over 3. Stage 3 or 4 ALS 4. Capable of understanding the information given and giving fully informed consent prior to any study specific procedures 5. Willing for the study team to contact patient’s GP about the study

Exclusion criteria

Exclusion criteria: 1. Patients at high risk of A&E admission for respiratory care unrelated to ALS because of underlying respiratory disease 2. Any patient involved in another study in which an intervention is designed to improve diaphragmatic function 3. Refusal of palliative care 4. Impaired cognition as judged by clinician

Design outcomes

Primary

MeasureTime frame
Number of inappropriate hospital admissions from A&E, in ALS patients, at 12 months

Secondary

MeasureTime frame
1. Reduction in morbidity or mortality associated with high dose oxygen use in ALS will be measured by determining the difference between arms of the number clinical incidents associated with high dose oxygen use 2. Tolerability of the smartphone app system in participants of the intervention arm will be compared at 3, 6, 9 and 12 months, for user and app generated data 3. Feasibility will be measured by the differences between user and App generated logs of A&E visits at 3, 6, 9 and 12 months and examination of the quality and usability of disease-progression data collected

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 1, 2026